UNS - Unilife Corporation

i have no idea if the building will be open on that date i would have thought mid october meanwhile the CEO gave a breifing this morning you can view it at this hyperlink
http://ir.unilife.com/eventdetail.cfm?eventid=85225
note that the financial position could be seen as worsening due to the drop off in revenue from sanofi while payments are still being made to build the factory and production line as wellas accumulate a supply of 1 ml syringes . I for one would have been very concerned if this deterioration had not occurred simply because if means that targets are being reached . It is normal for a start up company to spend more than it brings in in this case the deterioration should be well and truly finished by march when the company expects to be in production of the unifill syringe
one very happy camper here

the CEO of UNilife is given a breifing at this conference which is occuring over the next two days
is there any significance in the fact that neither BD or Coviden are presenting

http://www.marketwatch.com/story/st...re-conference-2010-09-15?reflink=MW_news_stmp
Stifel Nicolaus Hosts Annual Healthcare Conference

BOSTON, MA, Sep 15, 2010 (MARKETWIRE via COMTEX) -- Stifel, Nicolaus & Company, Incorporated, a full-service brokerage and investment banking firm, will host its Annual Healthcare Conference, September 15-17, 2010 at the Four Seasons Hotel in Boston. Institutional investors and company management will gather for this three-day conference, which will focus on opportunities and challenges in the healthcare industry for the remainder of 2010 and beyond.


The conference will showcase presentations from over 180 established and emerging public and private companies, including those engaged in biotechnology, diagnostics, healthcare IT & services, life science technology, major and specialty pharmaceuticals, and medical devices.

"We remain committed to broadening and deepening our coverage of the healthcare sector, one of the most important areas of growth in the U.S. economy. Despite broad economic weakness over the last year, healthcare spending continues to increase as a percentage of GDP. According to the Office of the Actuary, Center for Medicare and Medicaid Services (CMS), aggregate Healthcare spending, at 17% of GDP in 2009, is expected to reach 21% by 2019. Healthcare will continue to outpace growth of the overall economy, in our opinion -- fueling robust, long-term investment opportunities," said Ronald J. Kruszewski, Chairman, President, and Chief Executive Officer of Stifel Financial Corp.

The conference commences Wednesday morning and will be led by Stifel Nicolaus' eight senior healthcare research analysts: Thomas Carroll, health services; Charles Chon, medical devices; Jerry Doctrow, healthcare providers & REITs; Steven Halper, healthcare information technology and pharmaceutical services; Thomas Kouchoukos, medical devices; Annabel Samimy, specialty pharmaceuticals; Maged Shenouda, biotechnology; and Stephen Willey, biotechnology. Analysts will offer insight into the major trends impacting their respective sectors.

In addition to company insights, our keynote presentations feature first-class talent who are expected to challenge our perspectives and provide additional insights on the current debate regarding healthcare reform. We are pleased to host Nancy-Ann DeParle, Director of the White House Office for Health Reform, and Arnold Milstein, MD, MPH, Professor of Medicine and Director of the Clinical Excellence Research Center, Stanford University.

A full list of company participants includes:

ACADIA Pharmaceuticals Inc. Achillion Pharmaceuticals Acura Pharmaceuticals, Inc. Affymax, Inc. Affymetrix, Inc. Agilent Technologies, Inc. Alder Biopharmaceuticals Inc. Alexion Pharmaceuticals, Inc. Alimera Sciences, Inc. Allergan, Inc.

Allscripts Healthcare Solutions, Inc. Alnylam Pharmaceuticals, Inc.

Alphatec Holdings, Inc. Altea Therapeutics Amedisys, Inc. American Medical Systems, Inc. AmerisourceBergen Corporation Anadys Pharmaceuticals, Inc. AngioChem

AngioDynamics, Inc. Arcadian Management Services, Inc.

Ardea Biosciences, Inc. ArQule, Inc. Array BioPharma Inc. Arstasis

athenahealth, Inc. AutoGenomics, Inc. Auxilium Pharmaceuticals, Inc. Beckman Coulter, Inc. BioBehavioral Diagnostics Company BioDelivery Sciences International, Inc. Biogen Idec Inc. BioMarin Pharmaceutical, Inc. Bio-Rad Laboratories, Inc.

Cadence Pharmaceuticals, Inc. CambridgeSoft Corporation Cardinal Health, Inc. Celator Pharmaceuticals, Inc. Celgene Corporation

Cempra Pharmaceuticals Centene Corporation Cephalon, Inc. Cepheid

Ceregene, Inc. Cerner Corporation Conceptus, Inc. Concert Pharmaceuticals Inc. ConforMIS, Inc CONMED Corporation Corcept Therapeutics Incorporated Covance Inc. Cubist Pharmaceuticals, Inc. Cumberland Pharmacueticals Inc. Cytochroma Inc. DFine, Inc.

Dionex Corporation Dyax Corp. EGEN, Inc. eHealth, Inc. Emdeon Corporation Endo Pharmaceuticals Eurand (US) Exactech, Inc.

Exelixis, Inc. Express Scripts, Inc. ForteBio

Genomic Health, Inc. Gen-Probe Incorporated Gentiva Health Services, Inc. Genzyme Corporation Geron Corporation Given Imaging Ltd. GlobeImmune, Inc. HealthSpring, Inc Hill-Rom Holdings, Inc. Human Genome Sciences, Inc. Idenix Pharmaceuticals, Inc. Ikonisys Inc. ImmunoGen, Inc. Inhibitex, Inc. Inovio Pharmaceuticals Inspire Pharmaceuticals, Inc. Insulet Corporation

Integra LifeSciences Corporation InterMune, Inc. ISIS Pharmaceuticals, Inc. ISTA Pharmaceuticals, Inc. Keryx Biopharmaceuticals Kindred Healthcare, Inc. Lexicon Pharmaceuticals, Inc. Ligand Pharmaceuticals Inc. Light Sciences Oncology Inc. Lincare Holdings Inc. Logical Therapeutics, Inc.

MacroGenics Inc. MAP Pharmaceuticals Inc. Masimo Corporation

McKesson Corporation MedAptus, Inc. MedAssets, Inc. Medicis Pharmaceutical Corporation MEDNAX, Inc. Medtronic, Inc. Meridian Bioscience, Inc. Merit Medical Systems, Inc. Merrimack Pharmaceuticals, Inc. Myriad Genetics, Inc. Natus Medical Incorporated Neoprobe Corporation NeurAxon Inc. Neurocrine Biosciences, Inc. Neuronetics, Inc. NeuroPace, Inc. Novadaq Technologies Inc. Novavax, Inc. NuPathe, Inc. Obagi Medical Products, Inc. Omnicare, Inc. Omnicell, Inc. OmniGuide, Inc.

OncoGenex Pharmaceuticals Inc Orion HealthCorp, Inc. Orthofix International N.V. Orthovita, Inc. Osiris Therapeutics, Inc. Owens & Minor, Inc. PAREXEL International Corporation PatientKeeper, Inc. PerkinElmer, Inc. Pharmacyclics, Inc. PharMerica Corporation

Precision Therapeutics, Inc. PTC Therapeutics, Inc. Qiagen N.V.

Quality Systems, Inc. RainDance Technologies Regado Biosciences, Inc. Regulus Therapeutics Inc. RehabCare Group, Inc. Response Biomedical Corporation Revance Therapeutics, Inc. Rib-X Pharmaceuticals, Inc. Rigel Pharmaceuticals, Inc. S*BIO Pte Ltd.

Salix Pharmaceuticals, Ltd. Santarus, Inc. SCYNEXIS, Inc. Seattle Genetics, Inc. Sigma-Aldrich Corporation SkinMedica, Inc. Small Bone Innovations, Inc. SonoSite, Inc. Spectrum Pharmaceuticals, Inc. Stereotaxis, Inc. Supernus Pharmaceuticals, Inc. SXC Health Solutions Corporation Symmetry Medical, Inc. T2 Biosystems, Inc.

Targacept, Inc. Tekmira Pharmaceuticals Corporation Teleflex Incorporated The Advisory Board Company The Cooper Companies, Inc.

The Ensign Group, Inc. The Spectranetics Corporation Theravance, Inc. Transcept Pharmaceuticals, Inc. TransEnterix, Inc. Tranzyme Pharma Trius Therapeutics U.S. Preventive Medicine Unilife Corporation Vanguard Health Systems Vapotherm

Vascular Solutions, Inc. Vical Incorporated ViroPharma Incorporated Vitae Pharmaceuticals Vital Images, Inc. Vivus, Inc.

WellCare Health Plans, Inc WellPoint, Inc. Wright Medical Group, Inc. XDx, Inc.

Company Information

Stifel Financial Corp. /quotes/comstock/13*!sf/quotes/nls/sf (SF 49.13, +0.48, +0.99%) is a financial services holding company headquartered in St. Louis, Missouri, that conducts its banking, securities, and financial services business through several wholly owned subsidiaries. Stifel clients are primarily served in the U.S. through 310 offices in 43 states and the District of Columbia through Stifel, Nicolaus & Company, Incorporated and Thomas Weisel Partners LLC, and in two Canadian provinces through Stifel Nicolaus Canada Inc. Clients in the United Kingdom and Europe are served through offices of Stifel Nicolaus Limited and Thomas Weisel Partners International Limited. Each of the broker-dealer affiliates provide securities brokerage, investment banking, trading, investment advisory, commercial and retail banking, and related financial services to individual investors, professional money managers, businesses, and municipalities. Stifel Bank & Trust offers a full range of consumer and commercial lending solutions. To learn more about Stifel, please visit the company's web site at www.stifel.com.

Large overseas order after trading closed maybe the spruiking is working Will be interesting if it follows through tonight

Might be a good old covering of shorts from our friends in the US of A, from what I've read the american side of UNS has been shorted quite a bit, and the big last trade of the day was an overseas trade sooo 1 + 1 usually equals 2.

If it isn't a covering of shorts, it'll lead to a short squeeze, it's an interesting development either way imo, and good for the share price short term. Medium to long term it's still looking good for UNS, progress on all fronts, happily holding on to my shares now they are back in the green.

Re: UNS - share price going down

UBIQUITOUS said:

I don't know why it is falling, but can tell you that the price will start to climb again on September 20 at 10:09 am

Click to expand...

The share price seems to be rising almost on cue, do you have a crystal ball at your house UBIQUITOUS?

Unilife Secures U.S. Government Financial Backing for the Completion of New Global Headquarters and Manufacturing Facility in York, PA

Construction of state-of-the-art safety syringe manufacturing facility remains on-schedule for completion in late-2010

LEWISBERRY, Pa., Oct 21, 2010 /PRNewswire via COMTEX News Network/ -- Unilife Corporation ("Unilife" or "Company") (Nasdaq: UNIS, ASX: UNS) today announced that it has secured U.S. Government financial backing to support the construction of its new global headquarters and manufacturing facility in York, Pennsylvania.

The U.S. Department of Agriculture (USDA) has agreed to guarantee $10 million of an $18 million mortgage Unilife has now obtained from Metro Bank of Harrisburg to support construction of the 165,000 square foot state-of-the-art facility.

Unilife previously qualified for an additional $5.4 million in grants and loans from the Commonwealth of Pennsylvania, the majority of which relates to the development of the York facility. The combined financial commitments by U.S. and Pennsylvania Government agencies represent approximately half of the total $31 million projected cost of the York facility.

Mr. Alan Shortall, Chief Executive Officer of Unilife, stated, "We wish to thank government leaders for their continued collaboration with Unilife. This round of government financial support improves our balance sheet and offers us access to capital under very favorable terms. The support and interest we have received at the federal and state level has been overwhelmingly positive.

"I believe this strong government backing reflects our status as a fast-growing Pennsylvania company that is committed to local high-skilled job creation, and the production of best-in-class syringes which can provide a safer environment for healthcare workers and enhanced care for patients."

Mr. Tom Williams, State Director of the USDA, stated, "The USDA is working to ensure that rural communities have the tools they need to expand economic opportunity and improve their quality of life. The USDA congratulates Unilife on its strong life science investment into central Pennsylvania, bringing with it high-skill jobs in a high-tech, fast growing market sector."

Michael J. Bunn, Vice President and Regional Manager of Metro Bank, stated, "Together with the USDA, Metro Bank is proud to help make possible the growth and job creation underway at Unilife and proud to have a positive impact on economic development in our region. We are also pleased to have another growing global company among our expanding portfolio."

To ensure facility construction timelines continue to align with the accelerated industrialization program for the Unifill(R) ready-to-fill (prefilled) syringe, Unilife has already invested approximately $10 million of its own cash reserves in the project. The Company does not expect it will be required to lay out any additional cash to finance the completion of the York facility.

Construction of the York facility remains fully on schedule for completion in late-2010. The facility has been designed by leading pharmaceutical architects to have the annual capacity to manufacture up to 400 million units of Unilife's proprietary range of safety syringes.

The York facility shall feature world-class manufacturing, environmental control and material handling systems that will maximize overall production efficiencies and meet the highest pharmaceutical standards for primary drug containers. It will incorporate eight Class 8 (100,000) and three Class 7 (10,000) clean rooms where environmental factors such as temperature, humidity and particulate matter will be tightly controlled. An advanced Water-for-Injection (WFI) system will meet established pharmaceutical standards of water purity required for the production of the Unifill(R) ready-to-fill syringe.

Additional amenities that further enhance Unilife's capacity to be a preferred supplier to pharmaceutical customers includes a product development center, a microbiology lab, quality inspection and control rooms and a fully segregated warehouse for efficient inventory management.

Since initial ground breaking commenced in December 2009, Unilife and its construction partners have made rapid progress in the development of the York facility. Activities completed to-date include the erection of all exterior walls and roofing, as well as the installation of cooling towers, piping and sprinklers in the 110,000 square foot production wing. Installation of clean rooms, air-conditioning and other essential systems in the production wing are also well under way, clearing the path for the scheduled installation of initial automated assembly lines and other production equipment later this year.

In addition, construction of the framework of the 54,000 square foot office wing, which will serve as Unilife's global headquarters and support management functions, has recently been completed. Unilife is targeting the relocation and consolidation of staff from its current Lewisberry sites to the new facility to occur in mid-December.

"We are excited by the progress we have made at the construction site for our new headquarters and manufacturing facility," continued Shortall. "Despite construction starting in December 2009, which marked the beginning of one of the worst winters on record in Pennsylvania's history, the construction of the facility remains on schedule. We are confident that the facility will be ready for operations by the end of this year to align with the industrialization program for the Unifill(R) syringe. This state-of-the-art facility, together with the rapid expansion of our operational capabilities and internal expertise, will help us meet anticipated demand for our products, and become a preferred, long-term supplier to a number of pharmaceutical companies."

Unilife has also secured zoning approval for a potential 100,000 square foot extension at the York facility that would increase total annual production capacity of the site to an optimal target of one billion units of Unilife's proprietary range of safety syringes.

Please visit the Unilife website (www.unilife.com) to see the progress and for a full description of the facility's capabilities. Photos of Unilife's York facility can be viewed at the site.

About Unilife Corporation

Unilife Corporation is a U.S.-based medical device company focused on the design, development, manufacture and supply of a proprietary range of retractable syringes. Primary target customers for Unilife products include pharmaceutical manufacturers, suppliers of medical equipment to healthcare facilities and patients who self-administer prescription medication. These patent-protected syringes incorporate automatic and fully-integrated safety features which are designed to protect those at risk of needlestick injuries and unsafe injection practices. Unilife is ISO 13485 certified and has FDA-registered medical device manufacturing facilities in Pennsylvania.

This press release contains forward-looking statements. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These forward-looking statements are based on management's beliefs and assumptions and on information currently available to our management. Our management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We do not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those described in "Item 1A. Risk Factors" and elsewhere in our registration statement on Form 10 and those described from time to time in our periodic reports which we file with the Securities and Exchange Commission.

General: UNIS-G

BLACKROCK IS THE LARGEST INSTITUTIONAL SHAREHOLDER OF 25 LISTED INSTITUTIONS HOLDING SHARES IN UNIS

Blackrock appears twice on UNIS insider list

Once as the single largest institutional shareholder with
1,044,382 shares and the second time as the fifth largest shareholder with 83,290 shares. This combined amount is nearly twice as much as the second largest institution Barclays Global 562452 shares however just to complicate matters further and show how committed Blackrock is to UNIS Blackrock owns Barclays through having purchased it in dec 2009
http://www.nyse.com/about/listed/blk.html

It is listed on the NYSE as BLK and a major shareholder is the Bank of America

The purchase of UNIS shares is consistent with the views of Bob Doll (not Bob Dole politician) vice chairman of Blackrock and chief equity strategist for Fundamental Equities who in his annual economic and market predictions for the next year given July 22 2010 predicted that Healthcare would be one of three growth areas in the USA and that investors should be overweight in healthcare shares .
http://www2.blackrock.com/global/home/News/index.htm

Just thought you might to know who they are and why they are here in a size that exceeds that which could be reasonably considered following our entry to the Russell index

trading halt re capital raising seems to be off market hopefully its to get a large number of assembly lines up in a hurry

Is this the company that went into administration a little while ago?

How is it back?

Did I read that the CEO has been given a $11m pay packet last year after the stock relisted and ran to the ground again?

I'm confused.

kennas said:

Did I read that the CEO has been given a $11m pay packet last year after the stock relisted and ran to the ground again?

I'm confused.

Click to expand...

His basic Salary was $428 019 , ( pretty low ), compensated by a Non-equity Incentive Plan payment of $200 000 , and then some expenses of $64 805 , for a total cash of $ 692 824.

He had stock awards of 7 742 240 and options of 2 652 120 .

pacestick said:

He had stock awards of 7 742 240 and options of 2 652 120 .

Click to expand...

Any idea what that was all for. Seems like an amazing amount for a company well in the red.

I'm still confused.

from memory they were tied to achieving targets re the agreement with sanofi aventis . He gets more when he signs another company which he has indicated he expects soon. I am more tied to the interesting situation that will occur as they start production for sanofi aventis probably in march or with a bit of luck late february.At that time Unilife willl be taking market share off the big boys at a level they cannot afford to ignore .
It should b e noted that one of the recruits to Unilife was a former engineer for Becton Dickson the worlds biggest producer of syringes and he is recorded as saying they were unable to come up with a ready to fill syringe that has all of the capabilities of the unifill despite trying for several years

pacestick said:

from memory they were tied to achieving targets re the agreement with sanofi aventis . He gets more when he signs another company which he has indicated he expects soon. I am more tied to the interesting situation that will occur as they start production for sanofi aventis probably in march or with a bit of luck late february.At that time Unilife willl be taking market share off the big boys at a level they cannot afford to ignore .
It should b e noted that one of the recruits to Unilife was a former engineer for Becton Dickson the worlds biggest producer of syringes and he is recorded as saying they were unable to come up with a ready to fill syringe that has all of the capabilities of the unifill despite trying for several years

Click to expand...

This all sounds incredibly familiar. I remember Constable who held about 5% of this when they were trying to get contracts years ago and in the end, pop. No contracts, bankrupt.

So what's the full story with the signing of Sanofi Aventis? Does this mean actual sales, or what?

kennas said:

This all sounds incredibly familiar. I remember Constable who held about 5% of this when they were trying to get contracts years ago and in the end, pop. No contracts, bankrupt.

So what's the full story with the signing of Sanofi Aventis? Does this mean actual sales, or what?

Click to expand...

It's been a long time coming for that SA contract. I was in UNS a year ago just before it listed on the Nasdaq and made a motza on it.

Been watching it ever since... promises promises.

Worth a look if the contracts come in ...if and when is the issue. And if not why not and what then?

This is the ann of the contract. It's not sales at all.

They've built a huge factory and hired 200 people without knowing if they'll sell anything... HUH?

Maybe this is more important than it looks to me..

The CEO got a $10m bonus for this??? WTF?


Unilife and sanofi-aventis Agree to Exclusivity List for UnifillTM Ready-to-Fill Syringe
Lewisberry, PA (March 3, 2010)

Unilife Corporation (“Unilife” or “Company”) (NASDAQ: UNIS; ASX: UNS), today announced that it has agreed to a list of therapeutic drug classes (“Exclusivity List”) within which sanofi-aventis has the exclusive right to purchase the UnifillTM ready-to-fill syringe.

Sanofi-aventis has secured exclusivity for the UnifillTM syringe (“Product”) within the full therapeutic classes of antithrombotic agents and vaccines until June 30, 2014 (“Period of Exclusivity”). These two therapeutic classes together represent the majority of all prefilled syringes consumed globally. Sanofi-aventis has also secured Product exclusivity in an additional six smaller sub-groups that fall within other therapeutic classes that Unilife believes represent new market opportunities in the pharmaceutical use of prefilled syringes.

The scope of the Exclusivity List allows Unilife to commence formal discussions with other pharmaceutical companies relating to the potential use of the UnifillTM syringe within a number of significant therapeutic classes that fall outside of those areas retained by sanofi-aventis.

In accordance with the Exclusive Agreement, sanofi-aventis will receive a ten year extension (“Additional Period”) on its Period of Exclusivity within a designated therapeutic class should sanofi-aventis purchase commercial quantities of the product prior to July 1, 2014. This extension will be reduced on a per therapeutic class basis to five years in the event that sanofi-aventis does not sell a minimum of 20 million units of the UnifillTM syringe for use with an injectable drug product to be marketed for this therapeutic class in at least one of the first five years of the Additional Period.

kennas said:

This is the ann of the contract. It's not sales at all.

They've built a huge factory and hired 200 people without knowing if they'll sell anything... HUH?

Maybe this is more important than it looks to me..

The CEO got a $10m bonus for this???.

Click to expand...

They no doubt believe that since sanofi Aventis gave them the money to build a production line a follow up sales order is in the bag .It is true that Sanofi Aventis is big enough to walk away from a 15 million dollar donation but i would have said the bias was to place a follow up order

pacestick said:

They no doubt believe that since sanofi Aventis gave them the money to build a production line a follow up sales order is in the bag .It is true that Sanofi Aventis is big enough to walk away from a 15 million dollar donation but i would have said the bias was to place a follow up order

Click to expand...

Yes I agree that on the surface of it there is good motivation to follow up with sales.

However, correct me if I'm wrong, if they don't follow up UNS have been unable to sell to anyone else for it's main use.

And SA don't need to buy anything until July 2014.

So, three and half year to wait until they might start paying off debt....



$10m for that agreement?

Maybe I'm seeing that wrong.

I would rate the chances of Sanofi Aventis not purchasing rtf syringes off Unilife in the next 12 months as about the same as Osama Ben laden becoming mayor of New York. The United states and the european union both have legislation in place requiring the safest syringes to be used There is no doubt that the Unilife range is demonstartably superior to all other known competitors .There is always of course the possibility of someone in an obscure place suddenly appearing with a superior product but that is a chance you have to take

pacestick said:

There is no doubt that the Unilife range is demonstartably superior to all other known competitors

Click to expand...

But they haven't sold just one single syringe?

I'll put ten bucks on OBL just for interest sake.

kennas said:

But they haven't sold just one single syringe?

Click to expand...

I dont know where you have got the idea that they havent sold any syringes from they have sold one ml syringes to both steston for resale in asia and a USA buying group for use in parts of the USA .